Board of Directors

 

Hans Henrik Munch-Jensen (chairman) is the CFO at NordEnergie Renewables A/S. Hans Henrik served as Executive Vice President, CFO of H. Lundbeck A/S from 1998 to 2007, where he was responsible for overseeing the company’s finance and investor relations activities. He previously served as a politics and finance columnist for the newspaper Dagbladet Børsen and as Vice President of the Copenhagen Stock Exchange. Hans Henrik currently serves as Chairman of the Board at Riddersalen Theater, and as member in the boards of Genmab A/S and PNN Medical. Hans Henrik received his master in Political Science from the University of Aarhus. Hans Henrik joined the Larix board in September 2011.

 

Thea Wulff Olesen is Managing Director of the listed company BioPorto A/S as well as the daughter company BioPorto Diagnostics A/S, www.BioPorto.com. Apart from the experience gained from the founding and development of BioPorto, Thea has previous experience from managerial posts in medicotechnology and other branches, as well as a post as company lawyer for several years. Thea has a Master in law, LL.M., from University of Copenhagen, 1992. Thea joined Larix board in September 2011.

 

Jens Peter Balling, MD, QPPV, Vice President, Regulatory Affairs, Pharmacovigilance and Clinical Quality Assurance at H. Lundbeck A/S, Denmark. Jens Peter is a medical doctor by training from Faculty of Medicine, Copenhagen University. Following five years of training at Copenhagen University Hospitals within Internal Medicine, Cardiology, ENT and Urology, Jens Peter joined the pharmaceutical industry working within pharmacovigilance (Leo Pharmaceutical, Novo Nordisk, Nycomed and Lundbeck, all placed in Denmark). For the last eleven years he has held the role of Head of Pharmacovigilance and Qualified Person for Pharmacovigilance. Jens Peter is an active member of the EFPIA Pharmacovigilance subcommittee and member of Council of Adverse Drug Reactions for the Danish Medical Agency.